Comparative Pharmacology
Head-to-head clinical analysis: RESTASIS versus RESTASIS MULTIDOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RESTASIS versus RESTASIS MULTIDOSE.
RESTASIS vs RESTASIS MULTIDOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcineurin phosphatase inhibitor; inhibits T-cell activation and inflammatory cytokine production by blocking dephosphorylation of nuclear factor of activated T-cells (NFAT).
Cyclosporine A is a calcineurin inhibitor immunosuppressant. It binds to cyclophilin, forming a complex that inhibits calcineurin, thereby blocking dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T-cells). This reduces transcription of pro-inflammatory cytokines (e.g., IL-2) and T-cell activation, decreasing ocular surface inflammation.
One drop of 0.05% ophthalmic emulsion in each eye twice daily (approximately 12 hours apart).
One drop in each eye twice daily, approximately 12 hours apart. Administered as an ophthalmic emulsion.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours, supporting once-daily dosing in clinical use for chronic dry eye disease.
Terminal half-life approximately 24 hours (range 18–36 h) following ocular administration, reflecting slow elimination from ocular tissues and systemic circulation.
Primarily fecal elimination (approximately 94% of the dose), with less than 1% excreted unchanged in urine. Renal elimination is a minor pathway.
Primarily biliary/fecal: ~85% of absorbed dose excreted in feces. Renal excretion minimal (<5%) as unchanged drug or metabolites.
Category C
Category C
Calcineurin Inhibitor Ophthalmic
Calcineurin Inhibitor Ophthalmic